The European Commission (EC) granted marketing authorization for Biogen Inc.’s Vumerity (diroximel fumarate) to treat adults with relapsing-remitting multiple sclerosis (MS).

Pfizer Inc. started a large study testing the company’s investigational oral antiviral drug for the prevention of Covid-19 infection among those who have been exposed to the virus.

Pfizer announced on Sept. 2 the dosing of the first patients in a Phase III trial assessing a single dose of the company’s investigational RSV bivalent prefusion F subunit vaccine candidate (RSVpreF) in adults ages 60 and older. One day earlier, Pfizer announced the initiation of a Phase II/III clinical study of 1,140 participants for an oral pill expected to be used in a broad population of Covid patients.

Pfizer Inc. started dosing in a mid-to-late-stage trial of the company’s oral antiviral therapy for Covid-19 in non-hospitalized, symptomatic adult patients.

Amylyx Pharmaceuticals announced an infusion of $135 million in Series C funds to support the late-stage development of the Boston-based company’s lead candidate, AMX0035, for amyotrophic lateral sclerosis (ALS). 

Migraine headaches can be reduced in frequency and severity by atopant, an oral therapy developed by AbbVie, according to data presented at the 2021 American Headache Society’s (AHS) Annual Scientific Meeting.

The U.S. Food and Drug Administration approved Aurinia Pharmaceuticals Inc.’s Lupkynis (voclosporin) in combination with a background immunosuppressive therapy regimen to treat adult patients with active lupus nephritis.

The U.S. Food and Drug Administration approved BioCryst Pharmaceuticals Inc.’s Orladeyo (berotralstat) for prophylaxis to prevent attacks of hereditary angioedema in adults and young patients 12 years and older.

For years, you’ve been replacing your patient’s testosterone. Maybe it’s time to consider replacing how it’s delivered. While there have been frequent, and prominent, new products developed for treating hypogonadism in the last 20 years, one particular type of option has been scarce – and it may be the one that patients want and/or prefer. […]

A therapy jointly developed by Switzerland’s Roche Holding AG and Cambridge, Mass.-based Blueprint Medicines Corp. was approved by the U.S. health regulator for the treatment of patients with a type of non-small cell lung cancer (NSCLC).